Jan S. Rosenbaum, Ph.D

Jan S. Rosenbaum, Ph.D

Company: Kurome Therapeutics

Job title: CEO & CSO


Revealing IRAK1/4 as an Emerging Target to Override Adaptive Resistance Heme Malignancies 2:00 pm

Reviewing IRAK1/4 signal transduction in cancer cells to inform future development Clarifying the involvement of IRAK1/4 kinase signaling in the development of adaptive resistance Identifying activated forms of IRAK4 in MDS/AML patients to inform effective drug selectionRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.